Hemoglobin decline above 2g/dl during Peginterferon alfa-2b (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR in patients with HCV genotype 1 and HCV genotype 2/3 infectio…
G Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, D Hartmann, A Heuser, M Bilzer · Zeitschrift für Gastroenterologie · 2013 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: It has been shown that anemia and the hemoglobin (Hb) decline during Peg2b/RBV treatment of genotype 1 (G1) infection predict favorable SVR rates (Sulkowski M, Gastroenterology 2010). However, approximately 50% of the patients with anemia received erythropoietin, which may have confounded the association between Hb decline and SVR. We here investigated whether the association between Hb decline and SVR can be confirmed for patients treated for HCV G1 and for HCV G2/3 infection in real-life without erythropoietin treatment for anemia. Methods: Data of patients treated for chronic hepatitis C within th…
